Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 64Breast Neoplasms 20Kidney Neoplasms 19Gastrointestinal Stromal Tumors 16Neoplasms 15Carcinoma, Non-Small-Cell Lung 10Neoplasm Metastasis 9Prostatic Neoplasms 8Urinary Bladder Neoplasms 7Brain Neoplasms 7Colorectal Neoplasms 6Neuroendocrine Tumors 5Carcinoma, Hepatocellular 5Carcinoma 5Thyroid Neoplasms 4Stomach Neoplasms 4Small Cell Lung Carcinoma 4Ovarian Neoplasms 4Liver Neoplasms 4Thyroid Cancer, Papillary 3Sarcoma 3Pancreatic Neoplasms 3Leukemia, Myelomonocytic, Chronic 3Kidney Diseases 3Glioblastoma 3Esophageal Neoplasms 3Clear-cell metastatic renal cell carcinoma 3Astrocytoma 3Adenoma, Islet Cell 3Adenocarcinoma, Follicular 3

Interventions

Trastuzumab 3Sugammadex 2Neostigmine 2Cisplatin 2valrubicin 1tucatinib 1pembrolizumab 1niraparib 1enfortumab vedotin 1avelumab 1atezolizumab 1Surveys and Questionnaires 1Sunitinib 1Standard of Care 1Rocuronium 1Pemetrexed 1Paclitaxel 1Nephroureterectomy 1Neoadjuvant Therapy 1Mitomycin 1Lymph Node Excision 1Glycopyrrolate 1Gemcitabine 1GSK-3326595 1Fulvestrant 1Docetaxel 1Cetuximab 1Afatinib 1Administration, Intravesical 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Urologic Neoplasms × Sunitinib × Clear all
NCT03091192 2026-04-14

Savolitinib vs. Sunitinib in MET-driven PRCC.

AstraZeneca

Phase 3 Active not recruiting
60 enrolled 15 charts
Genitourinary

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡